P53 isoforms: Key regulators of the cell fate decision

Cold Spring Harbor Perspectives in Medicine

Volumn 6, Issue 8, 2016, Pages

  Joruiz, Sebastien M ^a   Bourdon, Jean Christophe ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; PROTEIN P53; SMALL INTERFERING RNA; ISOPROTEIN; MESSENGER RNA;

ALTERNATIVE RNA SPLICING; AMINO ACID SEQUENCE; ANIMAL MODEL; ARTICLE; CANCER THERAPY; CELL FATE; DEGENERATIVE DISEASE; DROSOPHILA; GENETIC VARIABILITY; HUMAN; INFLAMMATION; INTRINSIC ACTIVITY; NEOPLASM; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PREMATURE AGING; PROMOTER REGION; PROTEIN EXPRESSION; REGULATORY MECHANISM; TISSUE REGENERATION; TRANSLATION INITIATION; ZEBRA FISH; ANIMAL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; MOUSE; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTIBODIES, MONOCLONAL; DROSOPHILA; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; MICE; MODELS, ANIMAL; NEOPLASMS; PROTEIN ISOFORMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53; ZEBRAFISH;

EID: 84982864590     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a026039     Document Type: Article

References (120)

1. Almog N, Li R, Peled A, Schwartz D, Wolkowicz R, Goldfinger N, Pei H, Rotter V. 1997. The murine C0-terminally alternatively spliced form of p53 induces attenuated apoptosis in myeloid cells. Mol Cell Biol 17: 713–722.
2. Almog N, Goldfinger N, Rotter V. 2000. p53-dependent apoptosis is regulated by a C-terminally alternatively spliced form of murine p53. Oncogene 19: 3395–3403.
3. Anensen N, Oyan AM, Bourdon JC, Kalland KH, Bruserud O, Gjertsen BT. 2006. A distinct p53 protein isoform signature reflects the onset of induction chemotherapy for acute myeloid leukemia. Clin Cancer Res 12: 3985–3992.
4. Anensen N, Hjelle SM, Van Belle W, Haaland I, Silden E, Bourdon JC, Hovland R, Tasken K, Knappskog S, Lønning PE, et al. 2012. Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia. Oncogene 31: 1533–1545.
5. Aoubala M, Murray-Zmijewski F, Khoury MP, Fernandes K, Perrier S, Bernard H, Prats AC, Lane DP, Bourdon JC. 2011. p53 directly transactivates D133p53a, regulating cell fate outcome in response to DNA damage. Cell Death Differ 18: 248–258.
6. Arai N, Nomura D, Yokota K, Wolf D, Brill E, Shohat O, Rotter V. 1986. Immunologically distinct p53 molecules generated by alternative splicing. Mol Cell Biol 6: 3232–3239.
7. Arsic N, Gadea G, Lagerqvist EL, Busson M, Cahuzac N, Brock C, Hollande F, Gire V, Pannequin J, Roux P. 2015. The p53 isoform D133p53b promotes cancer stem cell potential. Stem Cell Rep 4: 531–540.
8. Avery-Kiejda KA, Zhang X D, Adams L J, Scott R J, Vojtesek B, Lane D P, Hersey P. 2008. Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin. Clin Cancer Res 14: 1659–1668.
9. Avery-Kiejda KA, Morten B, Wong-Brown MW, Mathe A, Scott RJ. 2014. The relative mRNA expression of p53 isoforms in breast cancer is associated with clinical features and outcome. Carcinogenesis 35: 586–596.
10. Bauer JH, Poon PC, Glatt-Deeley H, Abrams JM, Helfand SL. 2005. Neuronal expression of p53 dominant-negative proteins in adult Drosophila melanogaster extends life span. Curr Biol 15: 2063–2068.
11. Bauer JH, Chang C, Bae G, Morris SN, Helfand SL. 2010. Dominant-negative Dmp53 extends life span through the dTOR pathway in D. melanogaster. Mech Ageing Dev 131: 193–201.
12. Bellini I, Pitto L, Marini MG, Porcu L, Moi P, Garritano S, Boldrini L, Rainaldi G, Fontanini G, Chiarugi M, et al. 2010. DN133p53 expression levels in relation to haplotypes of the TP53 internal promoter region. Hum Mutat 31: 456–465.
13. Bernard H, Garmy-Susini B, Ainaoui N, Van Den Berghe L, Peurichard A, Javerzat S, Bikfalvi A, Lane DP, Bourdon JC, Prats AC. 2013. The p53 isoform, D133p53a, stimulates angiogenesis and tumour progression. Oncogene 32: 2150–2160.
14. Boldrup L, Bourdon JC, Coates PJ, Sjostrom B, Nylander K. 2007. Expression of p53 isoforms in squamous cell carcinoma of the head and neck. Eur J Cancer 43: 617–623.
15. Bourdon JC, Deguin-Chambon V, Lelong JC, Dessen P, May P, Debuire B, May E. 1997. Further characterisation of the p53 responsive element—Identification of newcandidate genes for trans-activation by p53. Oncogene 14: 85–94.
16. Bourdon JC, Fernandes K, Murray-Zmijewski F, Liu G, Diot A, Xirodimas DP, Saville MK, Lane DP. 2005. p53 isoforms can regulate p53 transcriptional activity. Genes Dev 19: 2122–2137.
17. Bourdon JC, Khoury MP, Diot A, Baker L, Fernandes K, Aoubala M, Quinlan P, Purdie CA, Jordan LB, Prats AC, et al. 2011. p53 mutant breast cancer patients expressing p53g have as good a prognosis as wild-type p53 breast cancer patients. Breast Cancer Res 13: R7.
18. Brodsky MH, Nordstrom W, Tsang G, Kwan E, Rubin GM, Abrams JM. 2000. Drosophila p53 binds a damage response element at the reaper locus. Cell 101: 103–113.
19. Brodsky MH, Weinert BT, Tsang G, Rong YS, McGinnis NM, Golic KG, Rio DC, Rubin GM. 2004. Drosophila melanogaster MNK/Chk2 and p53 regulate multiple DNA repair and apoptotic pathways following DNA damage. Mol Cell Biol 24: 1219–1231.
20. Campbell HG, Slatter TL, Jeffs A, Mehta R, Rubio C, Baird M, Braithwaite AW. 2012. Does D133p53 isoform trigger inflammation and autoimmunity? Cell Cycle 11: 446–450.
21. Camus S, Menendez S, Fernandes K, Kua N, Liu G, Xirodimas DP, Lane DP, Bourdon JC. 2012. The p53 isoforms are differentially modified by Mdm2. Cell Cycle 11: 1646–1655.
22. Candeias MM, Powell DJ, Roubalova E, Apcher S, Bourougaa K, Vojtesek B, Bruzzoni-Giovanelli H, Fahraeus R. 2006. Expression of p53 and p53/47 are controlled by alternative mechanisms of messenger RNA translation initiation. Oncogene 25: 6936–6947.
23. Chambers SK, Martinez JD. 2012. The significance of p53 isoform expression in serous ovarian cancer. Future Oncol 8: 683–686.
24. Chen J, Ruan H, Ng SM, Gao C, Soo HM, Wu W, Zhang Z, Wen Z, Lane DP, Peng J. 2005. Loss of function of def selectively up-regulates D113p53 expression to arrest expansion growth of digestive organs in zebrafish. Genes Dev 19: 2900–2911.
25. Chen J, Ng SM, Chang C, Zhang Z, Bourdon JC, Lane DP, Peng J. 2009. p53 isoform D113p53 is a p53 target gene that antagonizes p53 apoptotic activity via BclxL activation in zebrafish. Genes Dev 23: 278–290.
26. Cheng R, Ford BL, O’Neal PE, Mathews CZ, Bradford CS, Thongtan T, Barnes DW, Hendricks JD, Bailey GS. 1997. Zebrafish (Danio rerio) p53 tumor suppressor gene: cDNA sequence and expression during embryogenesis. Mol Mar Biol Biotechnol 6: 88–97.
27. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. 1994. Crystal structure of a p53 tumor suppressor–DNA complex: Understanding tumorigenic mutations. Science 265: 346–355.
28. Craig AL, Blaydes JP, Burch LR, Thompson AM, Hupp TR. 1999. Dephosphorylation of p53 at Ser20 after cellular exposure to low levels of non-ionizing radiation. Oncogene 18: 6305–6312.
29. Davidson WR, Kari C, Ren Q, Daroczi B, Dicker AP, Rodeck U. 2010. Differential regulation of p53 function by the N-terminal DNp53 and D113p53 isoforms in zebrafish embryos. BMC Dev Biol 10: 102.
30. De la Cova C, Senoo-Matsuda N, Ziosi M, Wu DC, Bellosta P, Quinzii CM, Johnston LA. 2014. Supercompetitor status of DrosophilaMyc cells requires p53 as a fitness sensor to reprogram metabolism and promote viability. Cell Metab 19: 470–483.
31. Dichtel-Danjoy ML, Ma D, Dourlen P, Chatelain G, Napoletano F, Robin M, Corbet M, Levet C, Hafsi H, Hainaut P, et al. 2013. Drosophila p53 isoforms differentially regulate apoptosis and apoptosis-induced proliferation. Cell Death Differ 20: 108–116.
32. Dumont P, Leu JIJ, Della Pietra AC III, George DL, Murphy M. 2003. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33: 357–365.
33. el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B. 1992. Definition of a consensus binding site for p53. Nat Genet 1: 45–49.
34. Fan Y, Lee TV, Xu D, Chen Z, Lamblin AF, Steller H, Bergmann A. 2010. Dual roles of Drosophila p53 in cell death and cell differentiation. Cell Death Differ 17: 912–921.
35. Flaman JM, Waridel F, Estreicher A, Vannier A, Limacher JM, Gilbert D, Iggo R, Frebourg T. 1996. The human tumour suppressor gene p53 is alternatively spliced in normal cells. Oncogene 12: 813–818.
36. Fujita K, Mondal AM, Horikawa I, Nguyen GH, Kumamoto K, Sohn JJ, Bowman ED, Mathe EA, Schetter AJ, Pine SR, et al. 2009. p53 isoforms D133p53 and p53b are endogenous regulators of replicative cellular senescence. Nat Cell Biol 11: 1135–1142.
37. Gambino V, De Michele G, Venezia O, Migliaccio P, Dall’ Olio V, Bernard L, Minardi SP, Della Fazia MA, Bartoli D, Servillo G, et al. 2013. Oxidative stress activates a specific p53 transcriptional response that regulates cellular senescence and aging. Aging Cell 12: 435–445.
38. Garritano S, Gemignani F, Palmero EI, Olivier M, Martel-Planche G, Le Calvez-Kelm F, Brugieres L, Vargas FR, Brentani RR, Ashton-Prolla P, et al. 2010. Detailed haplotype analysis at the TP53 locus in p.R337H mutation carriers in the population of Southern Brazil: Evidence for a founder effect. Hum Mutat 31: 143–150.
39. Gong L, Gong H, Pan X, Chang C, Ou Z, Ye S, Yin L, Yang L, Tao T, Zhang Z, et al. 2015. p53 isoform D113p53/ D133p53 promotes DNA double-strand break repair to protect cell from death and senescence in response to DNA damage. Cell Res 25: 351–369.
40. Grover R, Ray PS, Das S. 2008. Polypyrimidine tract binding protein regulates IRES-mediated translation of p53 isoforms. Cell Cycle 7: 2189–2198.
41. Grover R, Sharathchandra A, Ponnuswamy A, Khan D, Das S. 2011. Effect of mutations on the p53 IRES RNA structure: Implications for de-regulation of the synthesis of p53 isoforms. RNA Biol 8: 132–142.
42. Hamard PJ, Barthelery N, Hogstad B, Mungamuri SK, Tonnessen CA, Carvajal LA, Senturk E, Gillespie V, Aaronson SA, Merad M, et al. 2013. The C terminus of p53 regulates gene expression by multiple mechanisms in a target-and tissue-specific manner in vivo. Genes Dev 27: 1868–1885.
43. Hinault C, Kawamori D, Liew CW, Maier B, Hu J, Keller SR, Mirmira RG, Scrable H, Kulkarni RN. 2011. D40 isoform of p53 controls b-cell proliferation and glucose homeostasis in mice. Diabetes 60: 1210–1222.
44. Hofstetter G, Berger A, Fiegl H, Slade N, Zorić A, Holzer B, Schuster E, Mobus VJ, Reimer D, Daxenbichler G, et al. 2010. Alternative splicing of p53 and p73: The novel p53 splice variant p53d is an independent prognostic marker in ovarian cancer. Oncogene 29: 1997–2004.
45. Hofstetter G, Berger A, Schuster E, Wolf A, Hager G, Vergote I, Cadron I, Sehouli J, Braicu EI, Mahner S, et al. 2011. D133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer. Br J Cancer 105: 1593–1599.
46. Hofstetter G, Berger A, Berger R, Zoric´ A, Braicu EI, Reimer D, Fiegl H, Marth C, Zeimet AG, Ulmer H, et al. 2012. The N-terminally truncated p53 isoform D40p53 influences prognosis in mucinous ovarian cancer. Int J Gynecol Cancer 22: 372–379.
47. Horikawa I, Fujita K, Jenkins LMM, Hiyoshi Y, Mondal AM, Vojtesek B, Lane DP, Appella E, Harris CC. 2014. Autophagic degradation of the inhibitory p53 isoform D133p53a as a regulatory mechanism for p53-mediated senescence. Nat Commun 5: 4706.
48. Jassim OW, Fink JL, Cagan RL. 2003. Dmp53 protects the Drosophila retina during a developmentally regulated DNA damage response. EMBO J 22: 5622–5632.
49. Jin S, Martinek S, Joo WS, Wortman JR, Mirkovic N, Sali A, Yandell MD, Pavletich NP, Young MW, Levine AJ. 2000. Identification and characterization of a p53 homologue in Drosophila melanogaster. Proc Natl Acad Sci 97: 7301–7306.
50. Kashio S, Obata F, Miura M. 2014. Interplay of cell proliferation and cell death in Drosophila tissue regeneration. Dev Growth Differ 56: 368–375.
51. Khan D, Sharathchandra A, Ponnuswamy A, Grover R, Das S. 2013. Effect of a natural mutation in the 50 untranslated region on the translational control of p53 mRNA. Oncogene 32: 4148–4159.
52. Khoury MP, Bourdon JC. 2011. p53 isoforms: An intracellular microprocessor? Genes Cancer 2: 453–465.
53. Khoury MP, Marcel V, Fernandes K, Diot A, Lane DP, Bourdon JC. 2013. Detecting and quantifying p53 isoforms at mRNA level in cell lines and tissues. Methods Mol Biol 962: 1–14.
54. Lane D, Levine A. 2010. p53 research: The past thirty years and the next thirty years. Cold Spring Harb Perspect Biol 2: a000893.
55. Lane DP, Cheok CF, Brown C, Madhumalar A, Ghadessy FJ, Verma C. 2010.Mdm2 and p53 are highly conserved from placozoans to man. Cell Cycle 9: 540–547.
56. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, Valentin-Vega YA, Terzian T, Caldwell LC, Strong LC, et al. 2004. Gain of function of a p53 hot spot mutation in a mouse model of Li–Fraumeni syndrome. Cell 119: 861–872.
57. Lu WJ, Amatruda JF, Abrams JM. 2009. p53 ancestry: Gazing through an evolutionary lens. Nat Rev Cancer 9: 758–762.
58. Mahmoudi S, Henriksson S, Corcoran M, Mendez-Vidal C, Wiman KG, Farnebo M. 2009. Wrap53, a natural p53 antisense transcript required for p53 induction upon DNA damage. Mol Cell 33: 462–471.
59. Maier B, Gluba W, Bernier B, Turner T, Mohammad K, Guise T, Sutherland A, Thorner M, Scrable H. 2004. Modulation of mammalian life span by the short isoform of p53. Genes Dev 18: 306–319.
60. Marabese M, Marchini S, Marrazzo E, Mariani P, Cattaneo D, Fossati R, Compagnoni A, Signorelli M, Moll UM, Codegoni AM, et al. 2008. Expression levels of p53 and p73 isoforms in stage I and stage III ovarian cancer. Eur J Cancer 44: 131–141.
61. Marcel V, Perrier S, Aoubala M, Ageorges S, Groves MJ, Diot A, Fernandes K, Tauro S, Bourdon JC. 2010a. D160p53 is a novel N-terminal p53 isoform encoded by D133p53 transcript. FEBS Lett 584: 4463–4468.
62. Marcel V, Vijayakumar V, Fernandez-Cuesta L, Hafsi H, Sagne C, Hautefeuille A, Olivier M, Hainaut P. 2010b. p53 regulates the transcription of its D133p53 isoform through specific response elements contained within the TP53 P2 internal promoter. Oncogene 29: 2691–2700.
63. Marcel V, Tran PLT, Sagne C, Martel-Planche G, Vaslin L, Teulade-Fichou MP, Hall J, Mergny JL, Hainaut P, Van Dyck E. 2011. G-quadruplex structures in TP53 intron 3: Role in alternative splicing and in production of p53 mRNA isoforms. Carcinogenesis 32: 271–278.
64. Marcel V, Petit I, Murray-Zmijewski F, Goullet de Rugy T, Fernandes K, Meuray V, Diot A, Lane DP, Aberdam D, Bourdon JC. 2012. Diverse p63 and p73 isoforms regulate D133p53 expression through modulation of the internal TP53 promoter activity. Cell Death Differ 19: 816–826.
65. Marcel V, Khoury MP, Fernandes K, Diot A, Lane DP, Bourdon JC. 2013. Detecting p53 isoforms at protein level. Methods Mol Biol 962: 15–29.
66. Marcel V, Fernandes K, Terrier O, Lane DP, Bourdon JC. 2014. Modulation of p53b and p53g expression by regulating the alternative splicing of TP53 gene modifies cellular response. Cell Death Differ 21: 1377–1387.
67. Martın FA, Perez-Garijo A, Morata G. 2009. Apoptosis in Drosophila: Compensatory proliferation and undead cells. Int J Dev Biol 53: 1341–1347.
68. Matlashewski G, Lamb P, Pim D, Peacock J, Crawford L, Benchimol S. 1984. Isolation and characterization of a human p53 cDNA clone: Expression of the human p53 gene. EMBO J 3: 3257–3262.
69. Medrano S, Burns-Cusato M, Atienza MB, Rahimi D, Scrable H. 2009. Regenerative capacity of neural precursors in the adult mammalian brain is under the control of p53. Neurobiol Aging 30: 483–497.
70. Meek DW, Anderson CW. 2009. Posttranslational modification of p53: Cooperative integrators of function. Cold Spring Harb Perspect Biol 1: a000950.
71. Mendes CS, Levet C, Chatelain G, Dourlen P, Fouillet A, Dichtel-Danjoy ML, Gambis A, Ryoo HD, Steller H, Mollereau B. 2009. ER stress protects from retinal degeneration. EMBO J 28: 1296–1307.
72. Mesquita D, Dekanty A, Milan M. 2010. A dp53-dependent mechanism involved in coordinating tissue growth in Drosophila. PLoS Biol 8: e1000566.
73. Mollereau B, Ma D. 2014. The p53 control of apoptosis and proliferation: Lessons from Drosophila. Apoptosis 19: 1421–1429.
74. Mondal AM, Horikawa I, Pine SR, Fujita K, Morgan KM, Vera E, Mazur SJ, Appella E, Vojtesek B, Blasco MA, et al. 2013. p53 isoforms regulate aging-and tumor-associated replicative senescence in T lymphocytes. J Clin Invest 123: 5247–5257.
75. Moore HC, Jordan LB, Bray SE, Baker L, Quinlan PR, Purdie CA, Thompson AM, Bourdon JC, Fuller-Pace FV. 2010. The RNA helicase p68 modulates expression and function of the D133 isoform(s) of p53, and is inversely associated with D133p53 expression in breast cancer. Oncogene 29: 6475–6484.
76. Morata G, Shlevkov E, Perez-Garijo A. 2011. Mitogenic signaling from apoptotic cells in Drosophila. Dev Growth Differ 53: 168–176.
77. Nutthasirikul N, Limpaiboon T, Leelayuwat C, Patrakitkomjorn S, Jearanaikoon P. 2013. Ratio disruption of the D133p53 and TAp53 isoform equilibrium correlates with poor clinical outcome in intrahepatic cholangiocarcinoma. Int J Oncol 42: 1181–1188.
78. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, Crowley D, Jacks T. 2004.Mutant p53 gain of function in two mouse models of Li–Fraumeni syndrome. Cell 119: 847–860.
79. Ollmann M, Young LM, Di Como CJ, Karim F, Belvin M, Robertson S, Whittaker K, Demsky M, Fisher WW, Buchman A, et al. 2000. Drosophila p53 is a structural and functional homolog of the tumor suppressor p53. Cell 101: 91–101.
80. Ou Z, Yin L, Chang C, Peng J, Chen J. 2014. Protein interaction between p53 and D113p53 is required for the anti-apoptotic function of D113p53. J Genet Genomics 41: 53–62.
81. Pavletich NP, Chambers KA, Pabo CO. 1993. The DNAbinding domain of p53 contains the four conserved regions and the major mutation hot spots. Genes Dev 7: 2556–2564.
82. Pehar M, O’Riordan KJ, Burns-Cusato M, Andrzejewski ME, del Alcazar CG, Burger C, Scrable H, Puglielli L. 2010. Altered longevity-assurance activity of p53:p44 in the mouse causes memory loss, neurodegeneration and premature death. Aging Cell 9: 174–190.
83. Pehar M, Ko MH, Li M, Scrable H, Puglielli L. 2014. P44, the “longevity-assurance” isoform of P53, regulates tau phosphorylation and is activated in an age-dependent fashion. Aging Cell 13: 449–456.
84. Peterson C, Carney GE, Taylor BJ, White K. 2002. reaper is required for neuroblast apoptosis during Drosophila development. Development 129: 1467–1476.
85. Pospısilova S, Brazda V, Amrichova J, Kamermeierova R, Palecek E, Vojtesek B. 2000. Precise characterisation of monoclonal antibodies to the C-terminal region of p53 protein using the PEPSCAN ELISA technique and a new non-radioactive gel shift assay. J Immunol Methods 237: 51–64.
86. Poyurovsky MV, Katz C, Laptenko O, Beckerman R, Lokshin M, Ahn J, Byeon IJL, Gabizon R, Mattia M, Zupnick A, et al. 2010. The C terminus of p53 binds the N-terminal domain of MDM2. Nat Struct Mol Biol 17: 982–989.
87. Ray PS, Grover R, Das S. 2006. Two internal ribosome entry sites mediate the translation of p53 isoforms. EMBO Rep 7: 404–410.
88. Reisman D, Balint E, Loging WT, Rotter V, Almon E. 1996. A novel transcript encoded within the 10-kb first intron of the human p53 tumor suppressor gene (D17S2179E) is induced during differentiation ofmyeloid leukemia cells. Genomics 38: 364–370.
89. Sawhney S, Hood K, Shaw A, Braithwaite AW, Stubbs R, Hung NA, Royds JA, Slatter TL. 2015. a-Enolase is upregulated on the cell surface and responds to plasminogen activation in mice expressing a D133p53a mimic. PLoS ONE 10: e0116270.
90. Senturk S, Yao Z, Camiolo M, Stiles B, Rathod T, Walsh AM, Nemajerova A, Lazzara MJ, Altorki NK, Krainer A, et al. 2014. p53C is a transcriptionally inactive p53 isoform able to reprogram cells toward a metastatic-like state. Proc Natl Acad Sci 111: E3287–E3296.
91. Sharathchandra A, Lal R, Khan D, Das S. 2012. Annexin A2 and PSF proteins interact with p53 IRES and regulate translation of p53 mRNA. RNA Biol 9: 1429–1439.
92. Shi H, Tao T, Huang D, Ou Z, Chen J, Peng J. 2015. A naturally occurring 4-bp deletion in the intron 4 of p53 creates a spectrum of novel p53 isoforms with anti-apoptosis function. Nucleic Acids Res 43: 1035–1043.
93. Silden E, Hjelle SM, Wergeland L, Sulen A, Andresen V, Bourdon JC, Micklem DR, McCormack E, Gjertsen BT. 2013. Expression of TP53 isoforms p53b or p53g enhances chemosensitivity in TP53(null) cell lines. PLoS ONE 8: e56276.
94. Simeonova I, Lejour V, Bardot B, Bouarich-Bourimi R, Morin A, Fang M, Charbonnier L, Toledo F. 2012. Fuzzy tandem repeats containing p53 response elements may define species-specific p53 target genes. PLoS Genet 8: e1002731.
95. Simeonova I, Jaber S, Draskovic I, Bardot B, Fang M, Bouarich-Bourimi R, Lejour V, Charbonnier L, Soudais C, Bourdon JC, et al. 2013. Mutant mice lacking the p53 C-terminal domain model telomere syndromes. Cell Rep 3: 2046–2058.
96. Simon R, Aparicio R, Housden BE, Bray S, Busturia A. 2014. Drosophila p53 controls Notch expression and balances apoptosis and proliferation. Apoptosis 19: 1430–1443.
97. Slatter TL, Hung N, Campbell H, Rubio C, Mehta R, Renshaw P, Williams G, Wilson M, Engelmann A, Jeffs A, et al. 2011.Hyperproliferation, cancer, and inflammation in mice expressing a D133p53-like isoform. Blood 117: 5166–5177.
98. Slatter TL, Hung N, Bowie S, Campbell H, Rubio C, Speidel D, Wilson M, Baird M, Royds JA, Braithwaite AW. 2015. D122p53, a mouse model of D133p53a, enhances the tumor-suppressor activities of an attenuated p53 mutant. Cell Death Dis 6: e1783.
99. Solomon H, Sharon M, Rotter V. 2014. Modulation of alternative splicing contributes to cancer development: Focusing on p53 isoforms, p53b and p53g. Cell Death Differ 21: 1347–1349.
100. Song W, Huo S, Lu¨ J, Liu Z, Fang X, Jin X, Yuan M. 2009. Expression of p53 isoforms in renal cell carcinoma. Chin Med J 122: 921–926.
101. Stieper BC, Kupershtok M, Driscoll MV, Shingleton AW. 2008. Imaginal discs regulate developmental timing in Drosophila melanogaster. Dev Biol 321: 18–26.
102. Storer NY, Zon LI. 2010. Zebrafish models of p53 functions. Cold Spring Harb Perspect Biol 2: a001123.
103. Takahashi R, Giannini C, Sarkaria JN, Schroeder M, Rogers J, Mastroeni D, Scrable H. 2013. p53 isoform profiling in glioblastoma and injured brain. Oncogene 32: 3165–3174.
104. Takahashi R, Markovic SN, Scrable HJ. 2014. Dominant effects of D40p53 on p53 function and melanoma cell fate. J Invest Dermatol 134: 791–800.
105. Tang Y, Horikawa I, Ajiro M, Robles AI, Fujita K, Mondal AM, Stauffer JK, Zheng ZM, Harris CC. 2013. Downregulation of splicing factor SRSF3 induces p53b, an alternatively spliced isoform of p53 that promotes cellular senescence. Oncogene 32: 2792–2798.
106. Terrier O, Josset L, Textoris J, Marcel V, Cartet G, Ferraris O, N’guyen C, Lina B, Diaz JJ, Bourdon JC, et al. 2011. Cellular transcriptional profiling in human lung epithelial cells infected by different subtypes of influenza A viruses reveals an overall down-regulation of the host p53 pathway. Virol J 8: 285.
107. Terrier O, Marcel V, Cartet G, Lane DP, Lina B, Rosa-Calatrava M, Bourdon JC. 2012. Influenza A viruses control expression of proviral human p53 isoforms p53b and D133p53a. J Virol 86: 8452–8460.
108. Terrier O, Diederichs A, Dubois J, Cartet G, Lina B, Bourdon JC, Rosa-Calatrava M. 2013. Influenza NS1 interacts with p53 and alters its binding to p53-responsive genes, in a promoter-dependent manner. FEBS Lett 587: 2965–2971.
109. Ungewitter E, Scrable H. 2010. D40p53 controls the switch from pluripotency to differentiation by regulating IGF signaling in ESCs. Genes Dev 24: 2408–2419.
110. Wallace M, Worrall E, Pettersson S, Hupp TR, Ball KL. 2006. Dual-site regulation of MDM2 E3-ubiquitin ligase activity. Mol Cell 23: 251–263.
111. Waskar M, Landis GN, Shen J, Curtis C, Tozer K, Abdueva D, Skvortsov D, Tavare´ S, Tower J. 2009. Drosophila melanogaster p53 has developmental stage-specific and sexspecific effects on adult life span indicative of sexual antagonistic pleiotropy. Aging 1: 903–936.
112. Wei J, Noto J, Zaika E, Romero-Gallo J, Correa P, El-Rifai W, Peek RM, Zaika A. 2012. Pathogenic bacterium Helicobacter pylori alters the expression profile of p53 protein isoforms and p53 response to cellular stresses. Proc Natl Acad Sci 109: E2543–E2550.
113. Weingarten-Gabbay S, Khan D, Liberman N, Yoffe Y, Bialik S, Das S, Oren M, Kimchi A. 2014. The translation initiation factor DAP5 promotes IRES-driven translation of p53 mRNA. Oncogene 33: 611–618.
114. Wells BS, Johnston LA. 2012. Maintenance of imaginal disc plasticity and regenerative potential in Drosophila by p53. Dev Biol 361: 263–276.
115. Wells BS, Yoshida E, Johnston LA. 2006. Compensatory proliferation in Drosophila imaginal discs requires Droncdependent p53 activity. Curr Biol 16: 1606–1615.
116. Wolf D, Harris N, Goldfinger N, Rotter V. 1985. Isolation of a full-length mouse cDNA clone coding for an immunologically distinct p53 molecule. Mol Cell Biol 5: 127–132.
117. Wu Y, Liu Y, Lee L, Miner Z, Kulesz-Martin M. 1994.Wildtype alternatively spliced p53: Binding to DNA and interaction with the major p53 protein in vitro and in cells. EMBO J 13: 4823–4830.
118. Wu D, Zhang Z, Chu H, Xu M, Xue Y, Zhu H, Zhang Z. 2013. Intron 3 sixteen base pairs duplication polymorphism of p53 contributes to breast cancer susceptibility: Evidence from meta-analysis. PLoS ONE 8: e61662.
119. Xue Y, Wang S, Feng X. 2009. Influence of magnesiumion on the binding of p53 DNA-binding domain to DNAresponse elements. J Biochem (Tokyo) 146: 77–85.
120. Yin Y, Stephen CW, Luciani MG, Fahraeus R. 2002. p53 Stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products. Nat Cell Biol 4: 462–467.